glp-1 mcas The Multifaceted Nature of GLP-1: Molecular Mechanisms and Signaling Pathways in Metabolic and Neurodegenerative Diseases

GLP-1 Receptor Agonists: A Game-Changing Discovery for Mast Cell Activation Syndrome

28.04

★★★★☆4.8 (126)

It's wild—but true: mast cells actually have GLP-1 receptors on them. So yes, using a GLP-1 agonist for mast cell activation syndrome (MCAS) is a thing—and in some cases, it really helps

26.62

★★★★★4.9 (98)

The GLP-1 Agonist Boom in ME/CFS, FM and Long COVID: Insights, Using it, Trials Underway

20.17

★★★★★5.0 (157)

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

26.10

★★★★★4.7 (84)

Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review

25.07

★★★★★4.9 (203)

A newly published case series reports that GLP-1 receptor agonists (like semaglutide and tirzepatide) may significantly improve symptoms in patients with mast cell activation syndrome (MCAS), even in those without diabetes or

23.56

★★★★★5.0 (176)

Full article: Berberine-induced glucagon-like peptide-1 and its mechanism for controlling type 2 diabetes mellitus: a comprehensive pathway review

24.58

★★★★★4.8 (132)